MONTREAL, Oct. 31, 2025 — Leads & Copy — Knight Therapeutics Inc. (TSX: GUD) has finalized the syndication of its US$100 million secured revolving credit facility.
The credit facility, announced on June 17, 2025, with National Bank of Canada, has expanded to include Citibank N.A., Canadian Imperial Bank of Commerce (CIBC), and The Toronto-Dominion Bank (“TD”).
The revolving credit facility has been increased to US$100 million with an accordion feature for an additional US$100 million, pending lender approval. The Credit Facility will support growth strategy and for working capital.
The Credit Facility has an initial maturity date of June 17, 2028, and can be extended annually. It can be drawn in USD or CAD at the SOFR or CORRA rate plus an applicable margin between 1.25% to 2.75%. In June 2025, Knight withdrew C$60 million to fund the Paladin acquisition.
Arvind Utchanah, Chief Financial Officer of Knight Therapeutics Inc., stated the credit facility strengthens the relationship with four banks and the financial flexibility positions them well for acquisitions and supports the growth of the business.
Investor Contact:
Samira Sakhia, President & Chief Executive Officer, T: 514.484.4483, Email: IR@knighttx.com
Arvind Utchanah, Chief Financial Officer, T. +598.2626.2344, Email: IR@knighttx.com
Source: Knight Therapeutics Inc.
